Spravato (esketamine) is a type of nasal spray medication and is most commonly associated with the general anesthetic Ketamine. While it is very similar, Spravato has a slightly different molecular makeup Ketamine that allows it to yield therapeutic results. Spravato serves as a rapid-acting antidepressant when combined with oral antidepressant therapy.
Spravato is FDA approved for the following diagnoses:
Major Depressive Disorder with Suicidal Ideation or Acts
Qualified Providers at Red Sands:
Paige Marshall - Psychiatric Mental Health Nurse Practitioner
Zach Shepherd - Psychiatric Mental Health Nurse Practitioner
More about Spravato
How & where is it Administered
Spravato is administered in an approved medical setting, by trained personnel. All clinics that administer Spravato (including Red Sands) have engaged in specialized instruction, and are monitored by a National Risk Evaluation and Mitigation Strategy (REMS) program. Red Sands Psychiatry is an approved Spravato administration clinic with multiple trained practitioners.
At Red Sands, patients receive Spravato in a safe, calming environment located within our office. Patients will administer Spravato by giving themselves 2-3 nasal sprays; following the administration of the medication, they are monitored for 2 hours by the provider and other trained, office clinicians.
What to Expect
Patient’s on Spravato typically feel relaxed and comfortable. It is an optimal time for a psychotherapy session, as they are typically not inhibited with fears. Red Sands Psychiatry welcomes and encourages patients to invite their therapist into our office, to participate in their patient’s Spravato session, and to facilitate a therapeutic experience.
As far as side effects, it is common for patients to experience mild nausea, some fatigue, possible elevation in blood pressure at peak of medication, and some disassociation.